TERAZOL 3 VAGINAL CREAM Rx
Generic Name and Formulations:
Janssen Pharmaceuticals, Inc.
Indications for TERAZOL 3 VAGINAL CREAM:
1 applicator or supp vaginally at bedtime for 3 consecutive nights.
Confirm diagnosis by KOH smears and/or cultures. If ineffective, reconfirm diagnosis before repeating therapy. Discontinue if anaphylaxis, toxic epidermal necrolysis, fever, chills, irritation, or sensitization occurs. Concomitant use of contraceptive diaphragm with supp: not recommended. Pregnancy (Cat.C). Nursing mothers: not recommended.
Crm: headache, dysmenorrhea, abdominal pain. Supp: localized burning, genital pain, fever, chills.
Crm—20g (w. applicator); Supp—3 (w. applicator)
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally